Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck Teams With PeptiDream

by Rick Mullin
May 11, 2015 | A version of this story appeared in Volume 93, Issue 19

Merck & Co. and Tokyo-based PeptiDream have formed a drug discovery and optimization partnership. The companies will use PeptiDream’s proprietary Peptide Discovery Platform System technology to generate macrocylic/constrained peptides against multiple targets of interest to Merck. Financial terms haven’t been disclosed. PeptiDream has similar collaborations with Amgen, AstraZeneca, Bristol-Myers Squibb, Novartis, and other major drug firms.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.